Bruce Dezube

Dr. Dezube has served as Senior Vice President and Head of Clinical Development since June 2021. Dr. Dezube joined Mustang from Alkermes Inc., where he served as Vice President and Clinical Head of Oncology. While at Alkermes, Dr. Dezube oversaw the advancement of the company’s interleukin-2 variant from Phase 1 to registrational studies for the treatment of cancers. Prior to Alkermes, Dr. Dezube spent more than 9 years with Millennium (now Takeda Oncology) and Tesaro (now GlaxoSmithKline), where he held positions of increasing responsibility related to the development of their oncology pipelines. Fields of industry focus included myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), lymphoma, ovarian cancer, breast cancer, melanoma, and renal cell cancer. Earlier in his career, Dr. Dezube was an Associate Professor of Medicine at Harvard Medical School/Beth Israel Deaconess Medical Center where he served as an Attending Physician for more than 20 years. There he served on the Board of Trustees and was the Director of the Experimental Therapeutics/Phase 1 unit, Director of AIDS Oncology, and Deputy Director of the Cancer Center Clinical Trials Office. He is triple board-certified – in internal medicine, hematology, and oncology and has authored more than 200 publications on PubMed. He completed his internal medicine residency training at Tufts/New England Medical Center and hematology-oncology fellowship at Beth Israel Deaconess Medical Center/Harvard Medical School.